Introduction
============

Ischemic stroke is a major cause of adult disability and ranks only behind cancer and cardiac disease as cause of death ([@B16]). As our current understanding of cerebral ischemia injury is greatly contributed by the notion that mitochondria are both a pivotal site for cell death through mitochondrial apoptotic pathways ([@B1]) and a central target of processes triggered by cerebral ischemia/reperfusion, such as elevation in intracellular Ca^2+^ ([@B42]) and reactive oxygen species (ROS) ([@B39]), it is not surprising that strategies aimed at protecting against cerebral ischemia/reperfusion damage have focused on mitochondria.

Mitochondria have a central role in cell death including apoptosis, necrosis, and necroptosis via mitochondrial membrane permeabilization ([@B23]; [@B53]). In response to pro-apoptotic stimuli, including ROS and Ca^2+^ overload, the inner mitochondrial membrane abrupt loss of permeability to small solutes ([@B12]; [@B5]). This phenomenon, which is known as mitochondrial permeability transition (MPT), results in dissipation of the MMP, release of apoptotic factors, osmotic swelling of the mitochondrial matrix, and eventually cell death ([@B17]; [@B47]).

The MPT is caused by the opening of a non-selective pore assembled at the junctions between the inner and outer mitochondrial membrane, the so-called 'MPT pore' (MPTP) ([@B17]). While a large number of studies pointed to various proteins such as VDAC, ANT, and F~1~F~O~ ATP-synthase complexes as to structural or regulatory MPTP components, however, the precise molecular mechanisms of MPTP remained a matter of debate until now ([@B22]; [@B3]; [@B8]). As a standalone exception, CypD has been ascribed an essential regulatory role in MPTP via robust genetic studies as early as in 2005 ([@B2]; [@B40]; [@B48]).

Cyclophilin D is a *ppif* gene product, a member of the immunophilin family of peptidylprolyl *cis-trans* isomerases ([@B18]), which is well known bind to mitochondrial ANT, thus promoting MPTP opening ([@B13]; [@B17]). Indeed, as a chaperone protein, CypD promotes the rearrangement of MPTP subunits to allow for channel formation ([@B18]; [@B13]; [@B7]). Recently study characterizes CypD-F~1~F~O~ ATP-synthase interaction from the point of view of MPTP formation, providing evidence that CypD targets both energy production and programmed cell death ([@B14]).

In line with this notion, the *Ppif^-/-^* genotype as well as the systemic administration of chemical CypD inhibitors such as CsA confer remarkable protection in animal models of ischemia/reperfusion injury *in vivo*, and resistant to H~2~O~2~-induced cell death *in vitro* ([@B40]; [@B20]; [@B48]; [@B11]). In addition to CsA and its derivatives, barely drugs have been validated as compounds specifically targeting CypD or functions of MPTP ([@B34]; [@B30]). What is more, the serious adverse reactions of these compounds limit the clinical application on cardiovascular diseases due to their immunosuppressive effects ([@B38]).

GA (3, 4, 5-trihydroxybenzoic acid, **Figure [1F-a](#F1){ref-type="fig"}**), an important plant-sourced polyphenolic compound ([@B41]), reduced non-steroidal anti-inflammatory drugs (NSAID)-induced gastropathy, and radiation cytotoxicity by blocking oxidative stress-mediated apoptosis ([@B36]; [@B46]). Our earlier studies identified that GA is a potential mitochondrial protective agent, which has significant neuroprotective effect in cerebral ischemia/reperfusion injury ([@B44]). Nevertheless, its mitochondrial protective mechanism remains unclear.

![**Gallic acid (GA) desensitizes MPTP via a signaling axis that involves CypD in liver mitochondria.** CRC was determined by the concentration of calcium required to trigger MPTP opening.**(A,B)** GA has a higher Ca^2+^ threshold than control mitochondria. **(C)** CsA (1 μM) robustly increases the number of spikes, consistent with the importance of MPTP in this process. **(D)** Menadione caused marked mitochondria swelling in a concentration-dependent manner, **(E)** whereas GA or CsA pre-incubated mitochondria were significantly less sensitive. Histogram comparing Δ*A*~540~ values (*A*~540~ ~max~--*A*~540~ ~min~) among groups (*n* = 10). **(F-a)** Chemical structure of GA. **(F-b)** The 3D structure of CypD obtained from Protein Data Bank (PDB ID: 2BIT). **(F-c)** Salt bridges to ASN 102, PHE 113, MET 61, ARG 55, and **(F-d)** an H-bond to ASN 102 make major contributions to the binding affinity for GA (Distance: 2.039, Estimated free energy of binding: --0.568). **(G)** Representative Immunoprecipitation analysis showed that Ca^2+^-induced increase of CypD binding to ANT-1 was blocked by CsA or GA (*n* = 6). GA desensitized liver mitochondria to the permeability transition via suppressing CypD expression. **(H)** Mitochondria isolated from mouse liver which pre-treatment with GA (100 mg/kg) once a day for 6 days. The level of mitochondrial swelling triggered by menadione **(I)** or Ca^2+^ **(J)** was significantly decreased following GA pre-treatment (*n* = 10). The release of Cyto C **(K)**, and the expression of CypD **(L)** were tested via Western Blotting (*n* = 6). COX IV, VDAC, and β-actin were used as loading controls. Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test. N.S. indicates a *P* value \> 0.05. ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group.](fphar-08-00184-g001){#F1}

Here, we reveal a role of GA in protecting mitochondria via MPTP inhibition. To our surprise, we found that GA not only prevented MPTP opening by specifically interacted with CypD, but also played a role in regulating CypD expression through activating extracellular regulated protein kinases (ERK)-dependent phosphorylation, which renders nerve cells more refractory to MPTP opening following H~2~O~2~ (a generator of oxidative stress) *in vitro* or MCAO injury *in vivo*. These results confirm GA is a novel inhibitor of MPTP, which inhibits apoptosis depending on regulating the ERK-CypD axis. To the best of our knowledge this is the first study describing a novel MPTP inhibitor with pharmacological effect on CypD expression.

Materials and Methods {#s1}
=====================

Chemicals, Preparation of Mitochondria, Docking, and Experimental Design
------------------------------------------------------------------------

Please see Supplementary Material.

Animals and Ethics Statement
----------------------------

Adult male C57BL/6 mice (18--22 g) and Sprague-Dawley rats (250--300 g) were purchased from Jiangsu University Laboratory Animals Center, Zhenjiang, China. All animal procedures used in this study were approved by the Ethics Committee for Animal Experimentation of Jiangsu University (UJS-20160012, in Supplementary Material). The drug treatment protocols of GA, CsA, and U0126 in this experiment were based on previous literature ([@B28]; [@B11]; [@B44]).

Mitochondrial Calcium Retention Capacity (CRC)
----------------------------------------------

Mitochondrial CRC was assessed fluorimetrically in the presence of the fluorescent Ca^2+^ indicator Calcium Green 5N by the QuantaMaster & TimeMaster Spectrofluorometer (Photon Technology International, QuantaMaster^TM^40, USA) at excitation/emission maxima of 505/535 nm. Mitochondria (0.5 mg) were diluted in CRC buffer (120 mM KCl, 10 mM NaCl, 1 mM KH~2~PO~4~, 10 mM MOPS, 20 mM HEPES-Tris, pH 7.2) containing 150 nM Calcium Green 5N. Mitochondria were pulse-loaded with CaCl~2~ (10 μM each). Compounds were added to the mitochondrial suspension 5 min before CaCl~2~ exposure. The ratio between the amounts of calcium required to trigger MPTP in the presence of the compound (CRC~i~) with respect to that required to induce MPTP in the absence of the compound (CRC~o~) was used for statistical analysis.

Mitochondrial Swelling
----------------------

Mitochondrial swelling assay buffer (120 mmol/L KCl, 10 mmol/L Tris-HCl, 20 mmol/L MOPS, 5 mmol/L KH~2~PO~4~, pH 7.4) containing mitochondrial solution at 1 mg/ml was placed in each well of a 96-well plate at 25°C. The swelling was measured with a spectrophotometer (Molecular Device, Spectra Max 190, USA) as a decrease in light scattering at 540 nm for 10 min. Compounds were added to the mitochondrial suspension 5 min before CaCl~2~ or menadione exposure. The difference (ΔA~540~) between the maximum A~540~ value (immediately after CaCl~2~ or menadione addition) and the minimum A~540~ value (10 min after CaCl~2~ or menadione addition) were used for statistical analysis.

Immunoprecipitation
-------------------

After pre-treatment with compounds for 5 min and 100 μM CaCl~2~ exposured to 10 min, the isolated liver mitochondria were lysed in PBS containing 1% TritonX-100 and protease inhibitors cocktail. The supernatant was precleared with Protein A/G beads for 2 h at 4°C, and 500 mg of precleared protein extracts were incubated with 1 μg of anti-CypD antibody or normal rabbit IgG overnight at 4°C. The precipitated complexes were washed in lysis buffer and bound proteins analyzed by immunoblots.

Western Blotting
----------------

Samples were prepared to isolation of mitochondria and cytosolic protein by a mitochondria isolation kit according to the manufacturer's guidelines. Equal amounts of proteins were resolved by SDS/polyacrylamide gel electrophoresis (PAGE) using 10--15% acrylamide, transferred onto polyvinylidene difluoride (PVDF) membranes, and blotted using the following commercially available antibodies: anti-CypD (1:500), anti-ANT (1:300), anti-VDAC (1:400), anti-Cyto C (1:300), anti-Caspase-3 (1:500), anti-Caspase-8 (1:300), anti-Cleaved-Caspase-9 (1:400), anti-ERK1/2 (1:500), and anti-p-ERK1/2 (1:500), anti-β-actin (1:4000), anti-COX IV (1:500) followed by incubation with the corresponding horseradish peroxidase-labeled secondary antibody (1:2000). Protein bands were visualized and analyzed using the Chemifluorescence Imaging Systems (GE, USA).

Induction of Transient Cerebral Ischemia
----------------------------------------

Transient cerebral ischemia was induced by MCAO according to the method of [@B27]. The rats were anesthetized with chloral hydrate (350 mg/kg intraperitoneal injection). To alleviate pain, animals received 0.05 mg/kg subcutaneous buprenorphine immediately after the reperfusion anesthesia. The level of rCBF was achieved using a laser-Doppler flowmeter (Moor Instruments, UK). Rats had a rCBF in 20% of the pre-ischemic baseline value 10 min after ischemia and to the 80% of baseline at 30 min after reperfusion were used in this study ([@B29]). Physiological parameters such as the mean arterial blood pressure and heart rate were all monitored by Power Lab System (AD Instruments, Australia). The rats in the sham operation group underwent vessel exposure without MCAO. Body temperature was regulated at 37.0 ± 0.5°C with a heating pad and lamp when necessary. The details of the exclusion criteria, the level of rCBF, and physiological parameters were shown in the Supplementary Material.

Assessment of Cerebral Infarct Volume
-------------------------------------

2,3,5-Triphenyl-tetrazolium chloride staining was carried out using methods previously published by [@B24]. Brain Infarct volumes were calculated according to the following formula: (contralateral volume-undamaged ipsilateral)/contralateral volume (%).

Histopathological Analysis
--------------------------

Rat brains were removed, fixed in 4% paraformaldehyde in phosphate-buffered saline for 72 h at room temperature, dehydrated through a graded ethanol series, and embedded in paraffin. Sections of 4--5 μm thick were cut in the coronal plane and stained with H & E staining, which was performed as previously described ([@B32]).

Immunostaining
--------------

Immunostaining methods were used as described previously ([@B15]). The following primary antibodies were used: anti-Cyto C (1:150), anti-Cleaved-Caspase-9 (1:100), and anti-NeuN (1:200). Following incubation with the primary antibody at 4°C overnight, sections were incubated for 90 min with Alexa Fluor 594-and Alexa Fluor 488-conjugated secondary antibodies (1:200) in blocking solution at room temperature. Finally, sections were incubated with DAPI for 10 min to detect nuclei. All the slices were visualized by fluorescent inverted microscope (Nikon, Ti-E Live Cell Imaging System, Japan).

Electron Microscopy
-------------------

Rats brains were removed, dissected, and the ipsilateral penumbra areas post-fixed in the same fixative for 2 h before transferring to 0.12 M PBS. Specimens were immersed in 1% OsO~4~ in cacodylate buffer, dehydrated in ethanol and embedded in epoxy resin. Ultrathin sections (60 nm) were obtained with an ultra microtome (Leica EM UC7) and then were stained with uranyl acetate and lead citrate for examination with a transmission electron microscope (TEM) at 80 kV (HITACHI, H-7650, Japan).

Cell Cultures and Treatments
----------------------------

Human neuroblastoma SH-SY5Y cells were cultured in 90% modified Eagle's medium-F12 medium and supplemented with 10% fetal bovine serum. All cultures were maintained in 10 cm tissue culture dishes to approximately 90% confluence in a humidified atmosphere of 5% CO~2~-95% air at 37°C. The SH-SY5Y cells were treated with H~2~O~2~ at concentration of 500 μM for 4 h to establish the MPTP opening. Various concentrations of GA (0.1, 1, 10 μM), EGF (10, 100 ng), and CsA (1 μM) were added into the cultures 24 h before the onset of H~2~O~2~-inducing MPTP opening. Cells were incubated with U0126 (1, 10 μM) in culture medium for 2 h before GA or EGF treatment, which was used to inhibit ERK phosphorylation as recommended by the manufacturer.

Plasmid Transfection
--------------------

Clustered regularly interspaced short palindromic repeats-CypD plasmid synthesized by Santa Cruz Biotechnology was transfected into SH-SY5Y cells using the UltraCruz Transfection Reagent. Samples were collected at 24 and 48 h, and the transfection efficiency was examined by Western bolt. According to the manufacturer's instructions and our experiment data, the cells were used following 48 h transfection. Control cells were treated control CRISPR activation plasmid in an identical way.

Cell Viability and Apoptosis
----------------------------

Cell viability was measured by MTT assay ([@B19]). The optical density was spectrophotometrically measured at 570 nm using a microplate reader (Molecular Device, Spectra Max 190, USA) with DMSO as the blank. Cell apoptosis was determined by the Annexin V-FITC/PI apoptosis detection kit. A total of 20,000 cells of each sample were analyzed by bivariate flow cytometry system (Becton-Dickinson, FACSCanto II, USA).

Assaying MPTP Opening in Live Cells
-----------------------------------

To obtain direct evidence of GA effect on MPTP, the Calcein AM-CoCl~2~ assay was performed as previously described ([@B6]). The results were visualized using fluorescent inverted microscope (Nikon, Ti-E Live Cell Imaging System, Japan). Alternatively, fluorescence intensity was monitored using flow cytometry (Becton-Dickinson, FACSCanto II, USA) at excitation/emission maxima of 490/515 nm.

Assessment of Mitochondrial Membrane Potential (MMP)
----------------------------------------------------

A cationic dye, JC-1, was used to monitor the MMP. Briefly, cells were treated JC-1 10 μM for 30 min incubation at 37°C. The results were visualized using fluorescent inverted microscope (Nikon, Ti-E Live Cell Imaging System, Japan). Alternatively, fluorescence intensity was monitored using flow cytometry (Becton-Dickinson, FACSCanto II, USA) at excitation/emission maxima of 585/590 nm (J-aggregates) and 514/529 nm (monomer).

Statistical Analyses
--------------------

Except neurological deficit scores, all values are expressed as the mean ± SD, and the statistical significance of difference between groups was determined by a two-way analysis of variance (ANOVA) test. Neurological deficit scores were expressed as the median, and the statistical significance of the difference between groups was determined by a non-parametric Mann Whitney test. A *P*-value \< 0.05 was considered to indicate statistical significance.

Results
=======

GA Inhibits MPTP in Liver Mitochondria in both Ca^2+^ and ROS Stimuli
---------------------------------------------------------------------

Matrix Ca^2+^ is the single most important factor for inducing MPTP ([@B5]; [@B17]). Here, mitochondrial CRC was assessed fluorimetrically in the presence of the fluorescent Ca^2+^ indicator Calcium Green 5N. As shown in **Figure [1](#F1){ref-type="fig"}**, control mitochondria buffered 30 μM CaCl~2~, and their buffering capacity was significantly increased after pre-incubation with 1 μM CsA, consistent with the importance of MPTP in this process (**Figures [1A,C](#F1){ref-type="fig"}** and Supplementary Table [1](#SM1){ref-type="supplementary-material"}; *n* = 10, *P* \< 0.01). As expected, mitochondria that pre-incubation with 10 μM GA buffered up to 60 μM CaCl~2~, strongly increased the level of CRC as observed in control mitochondria (**Figures [1A,B](#F1){ref-type="fig"}** and Supplementary Table [1](#SM1){ref-type="supplementary-material"}; *n* = 10, *P* \< 0.01).

We further assessed MPTP sensitivity to the oxidant menadione, which acts as a potent MPTP inducer through promoting oxidative stress ([@B12]). The ΔA~540~ value of the mitochondria exposed to menadione at concentrations of 50--200 μM for 10 min increased to 0.1566 ± 0.01, 0.1975 ± 0.02, and 0.2203 ± 0.01 of the control value, respectively (**Figure [1D](#F1){ref-type="fig"}**; *n* = 10). Menadione caused marked mitochondria swelling, whereas CsA pre-incubated mitochondria were significantly less sensitive (**Figure [1E](#F1){ref-type="fig"}**; *n* = 10, *P* \< 0.01). Importantly, GA prevent mitochondrial swelling induced by stimuli independent of calcium overload (**Figure [1E](#F1){ref-type="fig"}**; *n* = 10, *P* \< 0.05), suggesting that it act as a genuine inhibitor of MPTP and not by affecting the calcium homeostasis.

GA Protects Brain Mitochondria against Cerebral Ischemia Reperfusion Injury
---------------------------------------------------------------------------

Next, we are interested in the MPTP activity of GA in cerebral ischemia insult, which is well known to favor activation of MPTP *in vivo* ([@B45]; [@B39]). The preliminary experiment is conducted to determine the time limited term under MCAO condition (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}; *n* = 4, *P* \< 0.05). No neurological deficits were observed in the sham treated rats, whereas rats subjected to MCAO were scored 2, 3, or 4 in the neurological assessment (Supplementary Figure [5A](#SM1){ref-type="supplementary-material"}; *n* = 20, *P* \< 0.01). The neurological deficits score in GA 50 mg/kg or CsA 10 mg/kg group was significantly reduced (Supplementary Figure [5A](#SM1){ref-type="supplementary-material"}; *n* = 20, *P* \< 0.05). By immunostained with NeuN, the numbers of pyramidal neurons in the hippocampus region were diminished dramatically after reperfusion, whereas the loss of hippocampal neurons was attenuated by GA (**Figures [2F-a,b](#F2){ref-type="fig"}**). The expression of cleaved-caspase-3, 8 and number of cleaved-caspase-9-positive cells (% of DAPI+ cells) were dramatically increased in the MCAO group compared with sham group, suggesting that both intrinsic and extrinsic apoptosis were trigged in cerebral ischemia (**Figures [2A,C--E-a5,b5,H](#F2){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Compared with the MCAO group, pre-treatment with GA had unequally sensitive in expression of cleaved-caspase-8 (**Figures [2A,C](#F2){ref-type="fig"}**; *n* = 4, *P* \> 0.05) and the number of cleaved-caspase-9-positive cells (% of DAPI+ cells) (**Figures [2E-b5,c5,H](#F2){ref-type="fig"}**; *n* = 4, *P* \< 0.01), suggesting that GA alleviates neuronal apoptosis dependent in the mitochondrial apoptotic pathways.

![**Gallic acid protects neuron against MCAO insult by the mitochondrial-dependent pathway.** GA downregulated brain mitochondrial CypD, inhibited the expression of Cleaved-caspase-8, and Cleaved-caspase-3 protein levels in brain mitochondria following transient cerebral ischemia (*n* = 4; **A--D**). VDAC, and β-actin were used as loading controls. GA protected brain mitochondrial and confers neuron survival after transient cerebral ischemia. **(E-a1--d1)** Representative TTC-stained coronal brain sections; white indicates infarcted tissue. **(E-a2--d2)** Representative H & E stained coronal brain sections (*n* = 4). Scale bars, 10 μm. **(E-a3--d3)** The TEM results evidence that GA protected brain mitochondria against MCAO injury (*n* = 4). Scale bars, 1 μm. **(E-a4**--**6, b4**--**6, c4**--**6, d4**--**6)** Immunohistochemistry depicting colocalization of Cleaved-caspase-9 with NeuN following 48 h reperfusion. Scale bars, 10 μm. **(F)** The numbers of pyramidal neurons in the hippocampus region were also diminished by Immunohistochemistry. Scale bars, 10 μm. **(G)** Histogram showing the infarct volume (% of contralateral hemisphere) in TTC-stained brain sections (*n* = 8). **(H)** Histogram showing the percentage of NeuN and Cleaved-caspase-9-positive cells which described as the number of positive cells/total number of cells (*n* = 4). Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test. ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus sham group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus MCAO group.](fphar-08-00184-g002){#F2}

Moreover, the mitochondrial protective effect of GA was further measured by the TEM and TTC assay. Notably, while the outer and inner membranes of mitochondria in sham group were clearly distinguishable, the mitochondria showed robustly swelling, vacuolization, disruption and loss of cristae following 48 h reperfusion (**Figures [2E-a3,b3](#F2){ref-type="fig"}**). This brought considerable relief in mitochondrial ultrastructure by pretreated with GA or CsA, which the cristae were slightly disrupted (**Figures [2E-c3,d3](#F2){ref-type="fig"}**), and the infarct volume was significantly reduced in GA pre-treatment (**Figures [2E-b1,c1,G](#F2){ref-type="fig"}**; *n* = 8, *P* \< 0.01) further confirmed that GA effectively protects brain mitochondria against ischemia/reperfusion injury.

GA Inhibits Cell Death and MPTP in Cultured SH-SY5Y Cells
---------------------------------------------------------

Since our *in vivo* data indicated MPTP is a key target of GA in pathologic neuron apoptosis, we next focus on validate this idea *in vitro*. Compared to the control group, H~2~O~2~ group was significantly decreased the cell viability (% of control) at 500 μM (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}; *n* = 5, *P* \< 0.01), and the number of apoptotic and necrotic cells were significantly increased, in accordance with the morphological observations (**Figures [3A-a1,a2,b1,b2,C,D](#F3){ref-type="fig"}**; *n* = 5, *P* \< 0.01). Notably, H~2~O~2~ elicited a rapid and almost complete decrease in the fluorescent density of mitochondrial calcein, a highly selective indicator of sustained MPTP opening *in situ* ([@B48]; [@B10]), while it was significantly reversed in the CsA pre-treated cells confirming loss of signal resulted from H~2~O~2~-induced opening of MPTP in our system (**Figures [4A-a2--a4,b2--b4,e2--e4,B](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01). This observation was in striking contrast to GA pre-treated cells, which considerably less SH-SY5Y cells mortality or apoptosis and retained more levels of calcein fluorescence than H~2~O~2~ treated cells in a concentration-dependent manner (**Figures [3A-b1,b2,e1,e2,B,C](#F3){ref-type="fig"}, [4A-b2,b4,c2,c4,d2,d4,B](#F4){ref-type="fig"}**; *n* = 4--5, *P* \< 0.01).

![**Gallic acid inhibits H~2~O~2~-induced SH-SY5Ys death by modulating the intrinsic pathway.** The mortality and apoptosis of SH-SY5Y cells were considerably less following pretreated with GA. **(A-a2--f2)** The number of apoptosis cells were detected by flow cytometry, in accordance with the morphological observations **(A-a1--f1)**. Histogram showing the percentage of cell viability **(B)**, apoptosis **(C)** and necrosis cells **(D)**, which described as the number of positive cells/total number of cells (*n* = 5). GA inhibited the expression of mitochondrial apoptotic signaling molecules induced by H~2~O~2~. Western Blotting **(E)**, and quantification **(F,G)** the relative intensities of the bands in each sample by quantity software (*n* = 4). Scale bars, 5 μm. Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test. ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus H~2~O~2~ group.](fphar-08-00184-g003){#F3}

![**Gallic acid desensitizes the MPTP induced by H~2~O~2~ in a CypD-dependent manner.** GA decreased the sensitivity of H~2~O~2~-induced MPTP induction in SH-SY5Y cells. **(A-a1--e1)** Representative endogenous Cyto C release in SH-SY5Y cells by Immunofluorescence analysis. **(A-a2--e2)** MPTP determined by Calcein-CoCl~2~ fluorescence. **(A-a3--e3)** Higher magnification and quantification **(A-a4--e4)** the calcein fluorescence tested by flow cytometry. The representative images show JC-1 aggregates **(A-a5--e5)**, monomers images **(A-a6--e6)**, and quantification **(A-a7--e7)** the JC-1 by flow cytometry, respectively. Histogram showing the level of calcein fluorescence **(B)**, and the ratio of JC-1 aggregates to JC-1 monomers (**C**; *n* = 4). Therapeutic effect of GA on MPTP inhibition was reversed by overexpression of CypD in SH-SY5Y cells. **(D)** Western blotting (upper) and quantification (lower) for mitochondrial CypD in SH-SY5Y cells pre-treated with GA or CsA following H~2~O~2~ for 4 h (*n* = 4). **(E)** Transfection efficiency was examined with Western Bolting. VDAC was used to loading control. **(F-a1,a2)** The levels of calcein fluorescence transfected with CypD or plasmid control, and treated with **(F-c1,c2)** or without **(F-b1,b2)** GA under H~2~O~2~ conditions were **(G)** quantificated by flow cytometry (*n* = 4). Scale bars, 5 μm. Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test. N.S. indicates a *P* value \> 0.05. ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus H~2~O~2~ group.](fphar-08-00184-g004){#F4}

As MMP could immediate dissipated by MPTP activation ([@B17]), the level of the MMP by JC 1 assay were also examined in this work. Compared to the control group, the red/green fluorescence intensity ratio in H~2~O~2~ treatment SH-SY5Y cells was significantly decreased (**Figures [4A-a5--a7,b5--b7,C](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01), while GA or CsA effectively blocked this event, consistent with the results of Calcein-CoCl~2~ assay (**Figures [4A-b5--b7,d5--d7,e5--e7,C](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01). These data further confirmed that GA could suppress oxidative stress-induced MPTP and cell death.

GA Inhibits SH-SY5Y Cells Death via the Mitochondrial Apoptotic Pathways
------------------------------------------------------------------------

As a second line of evidence for the inhibition of GA on MPTP, the expression of mitochondrial apoptotic signaling molecules, including the initiator Cyto C, mediator caspase-9, and effector caspase-3 were measured by Western Blot. As shown in **Figure [3E](#F3){ref-type="fig"}**, the release of Cyto C, the expression of cleaved-caspase-9 and -3 were observed with a 4-, 9-, and 7-fold increase, respectively, when compared to the control cells (**Figures [3E,F,G,4A-a1,b1](#F3){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Notably, compared with H~2~O~2~ treated cells, GA significantly reduced the expression of Cyto C, cleaved-caspase-9 and -3 confirming that GA inhibits H~2~O~2~-induced cells death by MPTP inhibition (**Figures [3E,F,G](#F3){ref-type="fig"}, [4A-b1,d1](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.05).

GA Directly Inhibits CypD Binding to ANT-1 in Liver Mitochondria
----------------------------------------------------------------

Of note, CypD is well known bind to mitochondrial ANT, thus promoting MPTP opening ([@B13]; [@B17]). Here, the physical interaction between CypD and ANT-1 was markedly enhanced by Ca^2+^ incubation, and prevented by CsA, consistent with these reports mentioned above (**Figure [1G](#F1){ref-type="fig"}**). GA abrogated Ca^2+^-induced CypD binding to ANT-1, indicating that the beneficial effects of GA are mediated, at least in part, by decreasing in CypD associated with ANT-1, subsequently blocking MPTP (**Figure [1G](#F1){ref-type="fig"}**). Moreover, the results of molecular docking between GA and CypD showed that GA was able to form electrostatic forces with ASN 102, PHE 113, MET 61, ARG 55 of CypD (**Figure [1F-c](#F1){ref-type="fig"}**). Notably, there is a hydrogen bond between GA and the residue ASN 102 of CypD (Distance: 2.039, Estimated free energy of binding: -0.568) (**Figure [1F-d](#F1){ref-type="fig"}**), in addition the binding site was correlated with previously reported binding site of CypD where CsA was bound ([@B21]).

CypD Is Suppressed by GA both *In vivo* and *In vitro*
------------------------------------------------------

Interestingly, mitochondria isolated from mouse liver in the pre-treatment with GA once a day for 6 days (**Figure [1H](#F1){ref-type="fig"}**) were desensitized to the permeability transition, and the level of mitochondrial swelling triggered by Ca^2+^ or menadione was significantly decreased compared with the control mitochondria (**Figures [1I,J](#F1){ref-type="fig"}**; *n* = 10, *P* \< 0.01). Importantly, it seemed more valence compared with mitochondria pre-treated GA 10 μM mentioned above, indicating that there may be other mechanisms at work. Western blotting data showed that not VDAC but CypD expression was significantly suppressed in liver mitochondria (**Figure [1L](#F1){ref-type="fig"}**; *n* = 6, *P* \< 0.05), suggesting that CypD is a potential target of GA in regulating the sensitivity of MPTP in the isolated mitochondria. Moreover, no significant difference in the release of Cyto C was observed in all samples, confirmed that the mitochondrial membrane remains well (**Figure [1K](#F1){ref-type="fig"}**; *n* = 6, *P* \> 0.05).

We reproduce this phenomenon in the cultured SH-SY5Y cells. As shown in **Figure [4D](#F4){ref-type="fig"}**, oxidative stress mediated by H~2~O~2~ caused greatly increase the expression level of CypD (**Figure [4D](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Compared with H~2~O~2~ treated cells, SH-SY5Y cells exposed to 0.1 or 10 μM of GA for 24 h displayed significantly decreased levels of CypD expression (**Figure [4D](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Importantly, it was worth noting that the decrease in brain mitochondrial CypD expression is indicative of the ability of GA to cross the blood-brain barrier, and suggesting that CypD is responsible for therapeutic benefit by GA via effects on MPTP inhibiting (**Figures [2A,B](#F2){ref-type="fig"}**; *n* = 4, *P* \< 0.01).

CypD Overexpression Abrogates GA-Induced MPTP Desensitization
-------------------------------------------------------------

To further evaluate whether CypD is essential for the sensitivity of GA in MPTP, cells were transfected with CPISPR-CypD to overexpress CypD. Incubation of SH-SY5Y cells with a CPISPR-CypD resulted in 120% increasing in CypD protein levels after 48 h transfection (**Figure [4E](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01). As shown in **Figure [4F](#F4){ref-type="fig"}**, SH-SY5Y cells overexpress CypD tended no significant loss of calcein fluorescence than non-transduced cells treated by 500 μM of H~2~O~2~ (**Figures [4F-b1,b2,G](#F4){ref-type="fig"}**; *n* = 4, *P* \> 0.05). Importantly, the calcein fluorescence signal in the GA pretreated cells was significantly higher than H~2~O~2~ treated cells (**Figures [4F-b1,c1,G](#F4){ref-type="fig"}**; *n* = 4, *P* \< 0.01), however, there was no significant charged in CypD overexpression SH-SY5Y cells following GA pretreated (**Figures [4F-b2,c2,G](#F4){ref-type="fig"}**; *n* = 4, *P* \> 0.05). These results confirmed that the inhibition of H~2~O~2~-induced MPTP by GA is dependent on CypD.

*In vitro* Modification of the ERK Phosphorylation Status Alters CypD Expression
--------------------------------------------------------------------------------

Of note, ERK is involved in mitochondrial dysfunction during both apoptotic and autophagy cell death-inducing pathways ([@B33]; [@B31]). As showed in **Figure [5](#F5){ref-type="fig"}**, EGF activated ERK in a concentration dependent manner, and it exerted the best effect at a concentration of 100 ng for 1 h (**Figures [5A,B](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.05). As expected, the level of phosphorylation ERK (p-ERK) were significantly inhibited by pre-treatment with U0126, a specificity inhibitor of ERK phosphorylation, at a concentration of 10 μM (**Figures [5A,B](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.01). In comparison with control cells, U0126 strongly increased the expression of CypD following 24 h of exposure, while EGF has the exactly opposite effect to that of CypD expression (**Figures [5A,C](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.05). Importantly, U0126 reversed the EGF-induced CypD overexpression, suggesting that the CypD expression in SH-SY5Y cells, at least in part, depends on ERK phosphorylation (**Figures [5A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.05).

![**Gallic acid alters CypD expression results in an enhancement of ERK phosphorylation.** The expression of CypD in SH-SY5Y cells partly depends on ERK phosphorylation. **(A)** the phosphorylation of ERK and the expression of CypD were determined by immunoblotting at 1 and 24 h following GA or EGF treatment, respectively. t-ERK and VDAC were used as a loading control. **(B,C)** Histogram showing the relative intensities of the bands in each sample was semi-quantification by quantity software (*n* = 4). ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus EGF (100 ng) group. **(D--F)** Transient cerebral ischemia increases ERK activity and downregulates CypD. The methods of tested and calculated the level of p-ERK and CypD were identical to (**A**; *n* = 4). ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus sham group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus Reperfusion 24 h group. CypD was a downstream target protein of ERK. **(G)** Transfection efficiency was examined with Western bolt. **(H,I)** The phosphorylation of ERK and the expression of CypD were determined by immunoblotting (*n* = 4). **(J)** The design for the *in vitro* experiment in **(K--M)** GA altered CypD expression through potentiating ERK phosphorylation. The methods of tested and calculated the level of p-ERK and CypD were identical to (**A**; *n* = 4).^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus U0126 (10 μM) group. Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test.](fphar-08-00184-g005){#F5}

Additionally, to explore whether CypD also regulated the phosphorylation of ERK, SH-SY5Y cells were transfected CPISPR-CypD to overexpress CypD. Incubation of SH-SY5Y cells with a CPISPR-CypD resulted in 105% increasing in CypD protein levels after 48 h transfection (**Figures [5G,H](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Compared with the control cells, CypD overexpression had no effect on the level of p-ERK, suggesting that CypD was a downstream target protein of ERK (**Figures [5G,I](#F5){ref-type="fig"}**; *n* = 4, *P* \> 0.05).

Alteration of CypD Expression by ERK Phosphorylation in MCAO Rats
-----------------------------------------------------------------

As a second line of evidence for the signaling of ERK-CypD, the effect of ERK in CypD expression during cerebral ischemia/reperfusion injury were studied *in vivo*. Of note, robust induction of p-ERK was expressed in the ischemic penumbra at the early stage of reperfusion, which involved in neuronal loss through caspase-3-mediated apoptosis ([@B25]; [@B26]). In comparison with sham rats, the level of p-ERK were significantly increased at 24 h, strongly declined at 48 h, and recovered at 72 h in the ischemic penumbral region following cerebral ischemia/reperfusion injury (**Figures [5D,E](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.01). Similarly, corresponds to overexpression of p-ERK, the expression of CypD were significantly decreased at 24 h, while robustly increased at 48 h after cerebral ischemia/reperfusion injury (**Figures [5D,F](#F5){ref-type="fig"}**; *n* = 4, *P* \< 0.05). Importantly, compared with sham group, the cleaved-caspase-3 were dramatically increased at 48 h following cerebral ischemia/reperfusion injury (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}; *n* = 4, *P* \< 0.05), further indicating that CypD-ERK axis involved in neuronal apoptosis at the early stage of reperfusion.

ERK Mediates GA-Induced Cytoprotective Effect via CypD Downregulation
---------------------------------------------------------------------

Since our data identified that phosphorylation of ERK is an early signaling event before the expression of CypD, whether ERK signaling participate in GA-induced CypD expression was determine. In SH-SY5Y cells, the phosphorylation of ERK is elevated in cells exposed to GA for 1 h when compared with control group (**Figures [5K,L](#F5){ref-type="fig"}, [6A,D](#F6){ref-type="fig"}**; *n* = 4, *P* \< 0.05). Notably, the GA-induced downregulation of CypD was abrogated by U0126, suggesting that the effect of GA on CypD, at least in part, results in an enhancement of ERK phosphorylation (**Figures [5K--M](#F5){ref-type="fig"}, [6A,E](#F6){ref-type="fig"}**; *n* = 4, *P* \< 0.01). The neurological deficits score in GA 50 mg/kg or U0126 30 mg/kg group was significantly reduced (Supplementary Figure [5B](#SM1){ref-type="supplementary-material"}; *n* = 12, *P* \> 0.05). Moreover, while U0126 significantly reduced the percent of the infarct volume and the expression of cleaved-caspase-3 following MCAO insult *in vivo* (**Figures [6H--J,L](#F6){ref-type="fig"}**; *n* = 4--8, *P* \< 0.05), no significant difference in the level of calcein fluorescence between U0126 and H~2~O~2~ group *in vitro* (**Figures [6B-c,d,e,C](#F6){ref-type="fig"}**; *n* = 4, *P* \> 0.05).

![**Extracellular signal-regulated kinases mediates GA-induced cytoprotective effect via CypD downregulation.** ERK is necessary for GA to prevent H~2~O~2~-induced apoptosis via CypD downregulation. **(A)** The phosphorylation of ERK and the expression of CypD were determined by immunoblotting. t-ERK, VDAC, and β-actin were used as a loading control. The design for the *in vitro* experiment in this figure was shown in **(B-a)**. **(B-b--f)** MPTP determined by Calcein-CoCl~2~ assay and **(C)** quantification by flow cytometry (*n* = 4). **(D--F)** Histogram showing the relative intensities of the bands in each sample was semi-quantification by quantity software (*n* = 4). ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus control group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus H~2~O~2~ group. ERK signaling triggered by GA were involved in MCAO-mediated apoptosis in rats. **(G)** The design for the *in vivo* experiment in this figure. **(H)** Representative TTC-stained coronal brain sections; white indicates infarcted tissue. **(I)** The phosphorylation of ERK and the expression of CypD were determined by immunoblotting. **(J)** Histogram showing the infarct volume (% of contralateral hemisphere) in TTC-stained brain sections (*n* = 8). **(K,L)** Quantification the bands in each sample was semi-quantification by quantity software (*n* = 4). ^\#\#^*P* \< 0.01, ^\#^*P* \< 0.05 versus sham group. ^∗∗^*P* \< 0.01, ^∗^*P* \< 0.05 versus MCAO group. Data reported as the means ± SD. *P* values were obtained using two-way analysis of variance (ANOVA) test.](fphar-08-00184-g006){#F6}

While GA was able to desensitize the MPTP in a CypD-dependent manner, whether this protection effect was related to ERK phosphorylation was investigated. As shown in **Figure [6](#F6){ref-type="fig"}**, combination treatment with U0126 abrogated GA-induced CypD downregulation, MPTP inhibition, and promoted caspase activation *in vitro* (**Figures [6A,B-c,d,f,C,F](#F6){ref-type="fig"}**; *n* = 4, *P* \> 0.05) and *in vivo* (**Figures [6H](#F6){ref-type="fig"}--[L](#F6){ref-type="fig"}**; *n* = 4, *P* \> 0.05), further confirmed the idea that ERK mediates GA-induced cytoprotective effect via CypD downregulation.

Discussion
==========

Here, for the first time, it demonstrates that the natural GA is a novel small molecule inhibitor of MPTP, which established this neuroprotective effect depending on regulating the ERK-CypD axis. Moreover, they are in contradiction with previous reports that inhibiting ERK phosphorylation could significantly attenuate apoptosis following cerebral ischemia/reperfusion injury ([@B51]; [@B50]).

Mitochondrial permeability transition pore results from relatively severe perturbations of intracellular redox and/or Ca^2+^ homeostasis, such as those that can be artificially imposed by ionophores (e.g., CaCl~2~) or potent oxidants (e.g., H~2~O~2~, menadione) *in vitro* ([@B48]; [@B10]), or those that are caused by ischemia/reperfusion insults *in vivo* ([@B40]; [@B45]). Earlier studies by our group identified that GA is a potential mitochondrial protective agent, which has significant neuroprotective effect in cerebral ischemia/reperfusion injury ([@B44]). Here, pretreatment with GA has a higher Ca^2+^ threshold, more refractory to mitochondrial swelling, calcein fluorescence and MMP dissipated induced by potent oxidants, deepen the knowledge on molecular actions triggered by GA, which result in MPTP inhibition. GA significantly reduced the expression of mitochondrial apoptotic signaling molecules further verify the above results. This similar results were also observed *in vivo*. Of note, cerebral ischemia triggers both intrinsic pathway that originates from mitochondrial crash associated stimulation of caspase-9 and the extrinsic pathway that derives from death receptors activation and subsequent stimulation of caspase-8 ([@B9]). GA brought considerable relief in brain mitochondrial ultrastructure, and had unequally sensitive in caspase-8 and 9 activation, emphasizing that GA alleviates neuronal apoptosis dependent in the mitochondrial apoptotic pathways. Totally, these *in vivo* and *in vitro* data demonstrated that GA is a genuine inhibitor of MPTP.

Indeed, cells depleted of putative core components of MPTP or treated with pharmacological modulators thereof exhibit an altered sensitivity to MPTP induction. However, whereas the generation of *Ppif^-/-^* mice and mice pretreatment with CsA formally attributed to CypD a key function in the molecular cascades that precipitate MPTP ([@B2]; [@B40]; [@B20]; [@B48]; [@B11]), the simultaneous knockout of Slc25a4/5 (encoding ANT-1/2) or VDAC-1/2/3 failed to protect specific cells from MPTP induction in mouse ([@B22]; [@B3]). At present, not VDAC but CypD were in significant depletion of GA affected cells both *in vivo* and *in vitro*, which abolished by CypD overexpression confirming GA desensitizes the MPTP induced by H~2~O~2~ is CypD dependent. This may explain why pretreated with GA was equally well protected SH-SY5Y cells from MPTP induction induced by H~2~O~2~ as CsA group, while GA has lower potency as a CypD inhibitor when compared with CsA. Thus, our findings confirmed that GA modulated the sensitivity of the MPTP through direct and indirect-interference with CypD.

The quest for key upstream regulators of the CypD yielded no better results. Actually, the transient or stable knockdown of p53, glycogen synthase kinase 3β, as well as F~1~F~O~ ATP-synthase, has been shown to modulate the sensitivity of cultured cells to MPTP-inducing stimuli by binding to CypD ([@B35]; [@B48]; [@B14]). In particular, only a few of these proteins have been mechanistically implicated in MPTP *in vivo* so far. Here, ERK has been etiologically implicated in brain injury following cerebral ischemia/reperfusion owing to its ability to inhibit MPTP by downregulating CypD expression, and the resistance displayed by GA were abrogated by co-administration of U0126 *in vitro* and *in vivo*, further confirming that the neuroprotective effect of GA is depending on regulating the ERK-CypD axis.

Of note, robust induction of ERK was expressed in the ischemic penumbra at the early stage of reperfusion, which involved in neuronal loss through caspase-3-mediated apoptosis ([@B25]; [@B26]). At present, the cleaved-caspase-3 were dramatically increased at 48 h following reperfusion, while the expression of ERK were decreased, which provides a direct approach in understanding the phosphorylation of ERK is beneficial to the recovery of neurons after cerebral ischemia. Our results challenge the view that inhibiting ERK activation could prevent neuronal damage following cerebral ischemia/reperfusion injury ([@B51]; [@B50]). At present, while U0126 has significant neuroprotective effect in cerebral ischemia/reperfusion injury, it did not promote cell survival following H~2~O~2~ injury. Of note, CypD-regulated MPTP is a crucial event during H~2~O~2~-induced cell death, definitively established by the CypD knockout mice ([@B2]; [@B48]). Hence, the failure of U0126 for H~2~O~2~-induced cell death could be understand to their inability to modulate MPTP. Importantly, ERK phosphorylation-induced apoptosis is activated in a Ca^2+^/Calmodulin (CaM)-dependent manner following cerebral ischemia ([@B54]). Despite GA probably not only targeted ERK-CypD pathway, the successful of GA as ERK activator for experimental stroke may be due to their ability to direct modulate mitochondrial CRC via MPTP inhibition.

Additionally, though GA has significant neuroprotective effects by inhibiting MPTP, the influence on the regulation of CYP450 by GA could not be ignored. Several studies have revealed that GA weakly and time-dependently inactivated CYP3A4 via its oxidative products, leading to more potential for toxicity of co-administered drugs ([@B43]; [@B37]; [@B49]). Of note, CYP3A4 plays a key role in metabolic clearance of Nifedipine and Amlodipine in humans, which were commonly prescribed calcium channel blocker for the treatment of hypertension ([@B55]; [@B52]). As a major cardiovascular risk factor for stroke, many patients of ischemic stroke are taking hypertensive medications ([@B4]). Blind applying GA in stroke patients suffered from hypertension will be blocked the metabolism of calcium antagonists, and may cause adverse reactions. Therefore, detailed studies on the interaction of GA and cardiovascular drugs have important practical significance, in which, the regulating of CYP450 systems are often required.

Conclusion
==========

This study identifies GA is a novel MPTP inhibitor, which might be promising for the treatment of stroke. We confirms CypD as a target protein through which GA exposure suppress the sensitivity of mitochondria to induction of MPTP, and proposes a model explaining the possible mechanism behind the downregulation CypD by GA in **Figure [7](#F7){ref-type="fig"}**. In consideration that MPTP plays a crucial role in mediating mitochondrial dysfunction cause for oxidative stress, we believe that GA could be beneficial in the treatment of wide variety of diseases ([@B45]; [@B1]; [@B39]).

![**Model illustrating the mechanism of cytoprotective effect by GA.** In addition to inhibit CypD binding to ANT, GA potentiates ERK phosphorylation, leading to a decrease in CypD expression, resulting in a desensitization to induction of MPTP, thus inhibiting caspase activation and ultimately giving rise to cellular survival.](fphar-08-00184-g007){#F7}
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